PYPD PolyPid Ltd.
Financings ·
PolyPid can now sell up to $15,000,000 of ordinary shares through Oppenheimer & Co. Inc., up from $8,250,000, paying a 3.0% commission. Its shares closed at $3.68 on November 25, 2025, and the supplement does not say how much cash the company has.
Holders of existing PolyPid warrants will exercise them for $26.7 million at $3.50 per share and receive new warrants at $4.50. The company ties the money to a Phase 3 trial whose effect size its release does not give.
The company says stockholders' equity is now about $7.5 million, up from $2.2 million at September 30, 2024. Nasdaq staff will keep monitoring, and the company could face delisting if it cannot show compliance in its next periodic report.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $23.8 million | $22.8 million |
| Net income (loss) | -$34.2 million | -$29.0 million |
| Cash from operations | -$27.9 million | -$22.0 million |
| Cash and equivalents | $6.4 million | $15.6 million |
Our latest story on this, dated Jan 17, 2025: "PolyPid says $14.5 million private placement restored Nasdaq equity compliance". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 17, 2025: "PolyPid says $14.5 million private placement restored Nasdaq equity compliance". The story links the filing or release it is based on. Read the story.
PolyPid Ltd. trades under the ticker PYPD on NASDAQ.
PolyPid Ltd. is listed on NASDAQ.
The SEC Central Index Key (CIK) for PolyPid Ltd. is 1611842. Its filings are on SEC EDGAR.
18,204,002 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-02-25.
Our directory records PolyPid Ltd. under Israel.
Our directory classifies PolyPid Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for PolyPid Ltd. is IL0011326795.
aibio.space lists PolyPid Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as L3.
PolyPid Ltd. reported a net loss of $34.2 million for the fiscal year ended Dec 31, 2025, and used $27.9 million of cash in operations, per its annual report to the SEC.
$23.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$6.4 million in cash at Dec 31, 2025, per its 20-F.
Our latest story on PolyPid, dated Nov 26, 2025: "PolyPid raises share sales program limit from $8,250,000 to $15,000,000". PolyPid can now sell up to $15,000,000 of ordinary shares through Oppenheimer & Co. Inc., up from $8,250,000, paying a 3.0% commission. Its shares closed at $3.68 on November 25, 2025, and the supplement does not say how much cash the company has. Source.
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio